<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="publisher-id">MEDI</journal-id>
      <journal-title-group>
        <journal-title>Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0025-7974</issn>
      <issn pub-type="epub">1536-5964</issn>
      <publisher>
        <publisher-name>Wolters Kluwer Health</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26937937</article-id>
      <article-id pub-id-type="pmc">4779034</article-id>
      <article-id pub-id-type="doi">10.1097/MD.0000000000002923</article-id>
      <article-id pub-id-type="art-access-id">02923</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>5700</subject>
        </subj-group>
        <subj-group>
          <subject>Research Article</subject>
          <subject>Clinical Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pineal Diffuse Large B-Cell Lymphoma Concomitant With Pituitary Prolactinoma: Possible Correlation Between 2 Distinguished Pathologies</article-title>
        <subtitle>A Case Report</subtitle>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Yeong-Jin</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Hee Kyung</given-names>
          </name>
          <degrees>MD, PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>Deok-Hwan</given-names>
          </name>
          <degrees>MD, PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jung</surname>
            <given-names>Shin</given-names>
          </name>
          <degrees>MD, PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Noh</surname>
            <given-names>Myung-Giun</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Jae-Hyuk</given-names>
          </name>
          <degrees>MD, PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Kyung-Hwa</given-names>
          </name>
          <degrees>MD, PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moon</surname>
            <given-names>Kyung-Sub</given-names>
          </name>
          <degrees>MD, PhD</degrees>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Cao.</surname>
            <given-names>Chun-xia</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff>From the Department of Neurosurgery (Y-JK, SJ, K-SM); Department of Internal Medicine (HKK, D-HY); and Departments of Pathology, Chonnam National University Research Institute of Medical Sciences (M-GN, J-HL, K-HL), Chonnam National University Hwasun Hospital and Medical School, Hwasun-gun, Jeollanamdo, South Korea.</aff>
      <author-notes>
        <corresp>Correspondence: Kyung-Sub Moon, Department of Neurosurgery, Brain Tumor Clinic and Gamma Knife Center, Chonnam National University Hwasun Hospital and Medical School, 322 Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeollanam-do 519-763, South Korea (e-mail: <email>moonks@chonnam.ac.kr</email>).</corresp>
        <corresp>Kyung-Hwa Lee, Department of Pathology, Chonnam National University Hwasun Hospital and Medical School, 322 Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeollanam-do 519-763, South Korea (e-mail: <email>mdkaylee@jnu.ac.kr</email>).</corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <month>2</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>03</day>
        <month>3</month>
        <year>2016</year>
      </pub-date>
      <volume>95</volume>
      <issue>8</issue>
      <elocation-id>e2923</elocation-id>
      <history>
        <date date-type="received">
          <day>1</day>
          <month>12</month>
          <year>2015</year>
        </date>
        <date date-type="rev-recd">
          <day>1</day>
          <month>2</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>2</day>
          <month>2</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2016 Wolters Kluwer Health, Inc. All rights reserved.</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0">
          <license-p>This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0, where it is permissible to download, share and reproduce the work in any medium, provided it is properly cited. The work cannot be changed in any way or used commercially. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0">http://creativecommons.org/licenses/by-nc-nd/4.0</ext-link></license-p>
        </license>
      </permissions>
      <self-uri xlink:type="simple" xlink:href="medi-95-e2923.pdf"/>
      <abstract>
        <title>Abstract</title>
        <p>This is the first reported case of pineal lymphoma with concomitant prolactin-producing pituitary adenoma.</p>
        <p>A 51-year-old male experienced worsening headaches accompanied by nausea, diplopia, and memory loss for 1 month. Cranial nerve examination revealed bilateral upward gaze limitation with convergence impairment, which is known as Parinaud syndrome. Magnetic resonance images revealed a mass in the pineal gland with a coexisting mass within the enlarged sella fossa. Hormone analysis revealed hyperprolactinemia. The pineal mass was removed without injuring the hypothalamus, brain stem, or any neighboring vessels. Pathology examination confirmed the diagnosis of diffuse large B-cell lymphoma (DLBCL) involving the pineal gland. After further studies, the pineal lymphoma was determined to be a secondary tumor from a gastric primary tumor. The patient died 6 months after diagnosis due to systemic progression of DLBCL.</p>
        <p>Although the mechanistic link between hyperprolactinemia and lymphoma progression has not been clarified on a clinical basis, high prolactin levels may contribute to the rapid progression and therapeutic resistance of the lymphoma.</p>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>OPEN-ACCESS</meta-name>
          <meta-value>TRUE</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Cerebral lymphoma is a malignant lymphocytic neoplasm that can occur as a primary tumor or as a secondary manifestation of systemic disease. Once considered a rare neoplasm, the incidence of central nervous system (CNS) lymphoma has increased significantly in recent decades.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> At initial diagnosis, a primary CNS lesion appears in approximately 1% to 2% of patients with non-Hodgkin lymphoma.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> Systemic lymphoma spreads to the CNS in 5.5% to 9.4% of cases and is associated with a poor prognosis.<sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref></sup> The occurrence of malignant lymphoma in the pineal region is extremely rare. Only 10 cases of primary or secondary pineal lymphomas, including the case in this study, have been reported in the literature to date.<sup><xref rid="R5" ref-type="bibr">5</xref>&#x2013;<xref rid="R13" ref-type="bibr">13</xref></sup></p>
      <p>Neuroendocrine and immune responses mutually affect each other via various interactions between the hormones/respective receptors and the immune system.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> Furthermore, elevated prolactin (PRL) levels are associated with the progression of hematologic diseases including multiple myeloma, acute myeloid leukemia, and non-Hodgkin lymphoma.<sup><xref rid="R15" ref-type="bibr">15</xref>&#x2013;<xref rid="R17" ref-type="bibr">17</xref></sup> Here, we report a case of pineal lymphoma as the first manifestation of gastric lymphoma and discuss the possible role of concomitant pituitary prolactinoma on lymphoma.</p>
    </sec>
    <sec>
      <title>CASE PRESENTATION</title>
      <p>A 51-year-old male experienced worsening headaches for 1 month, which were accompanied by nausea, diplopia, and mild memory loss. He had no significant medical history and was not taking any medications including antipsychotics. On admission, the liver and spleen were not palpable, and there were no palpable superficial lymph nodes. Neurological examination revealed no evidence of impaired mental status, gait difficulties, or sensory or motor deficits. Positive neurological findings included bilateral upward gaze limitation with convergence impairment, also called Parinaud syndrome. Magnetic resonance (MR) image of the brain revealed a 2&#x200A;&#xD7;&#x200A;2&#x200A;&#xD7;&#x200A;2&#x200A;cm mass in the pineal gland with a concomitant 1.5&#x200A;&#xD7;&#x200A;1.5&#x200A;&#xD7;&#x200A;1.2&#x200A;cm mass within the enlarged pituitary fossa (Figure <xref ref-type="fig" rid="F1">1</xref>A&#x2013;D). The pineal mass showed iso- to hypointensity on T<sub>1</sub>- and T<sub>2</sub>-weighted MR images and heterogeneous enhancement by gadolinium administration. It was a multilobulated mass that extended into the hypothalamus and midbrain. The lesion showed perilesional edema and internal calcification. Obstructive hydrocephalus due to stenosis of the aqueduct of Sylvius was also seen. Laboratory findings upon admission included a 6.7&#x200A;&#xD7;&#x200A;10<sup>3</sup>/mm<sup>3</sup> white blood cell count with a normal differentiation, a hemoglobin level of 10.8&#x200A;g/dL, and a platelet count of 360&#x200A;&#xD7;&#x200A;10<sup>3</sup>/mm<sup>3</sup>. Hormonal analysis indicated hyperprolactinemia (977.7&#x200A;ng/mL; normal, 2.8&#x2013;29.3&#x200A;ng/mL). The patient's serum thyroid-stimulating hormone (TSH) and free T4 values were 0.652&#x200A;&#x3BC;IU/mL (normal, 0.8&#x2013;1.71&#x200A;&#x3BC;IU/mL) and 0.770&#x200A;ng/dL (normal, 0.4&#x2013;4.8&#x200A;ng/dL). Coagulation, hepatic, and renal profiles were within normal limits. A serologic study for human immunodeficiency virus was negative. Tumor markers for a pineal mass, such as &#x3B1;-fetoprotein, human chorionic gonadotropin, and carcinoembryonic antigen, were within normal ranges. Due to the presumptive diagnosis of a nongerminomatous, parenchymal, or glial tumor on the pineal gland, surgery was performed using the occipital transtentorial approach. A slightly hard, dark red mass was located in the pineal gland and posterior third ventricle. The mass had internal calcification and was easily demarcated from the peritumoral brain parenchyma. Some portions of the mass that adhered to surrounding venous structures required sharp dissection. Frozen biopsy diagnosis of the pineal lesion suggested a pineoblastoma. The mass was removed completely without injuring the hypothalamus, brain stem, or any neighboring vessels.</p>
      <fig id="F1" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Preoperative magnetic resonance (MR) imaging. (A) A hypo- to isointense mass was detected at the pineal region on the T<sub>1</sub>-weighted image. (B) Marked peritumoral edema was shown surrounding the pineal mass on the T<sub>2</sub>-weighted image. (C) Axial image with gadolinium enhancement demonstrated multilobulation and heterogenous enhancement of the pineal mass, with a margin indistinct from the surrounding hypothalamus and midbrain, and hydrocephalus caused by obstruction of the aqueduct of Sylvius. (D) Note a strongly enhanced mass located entirely within the enlarged sellar turcica (asterisk).</p>
        </caption>
        <graphic xlink:href="medi-95-e2923-g001"/>
      </fig>
      <p>Histopathology revealed diffuse infiltration of large lymphocytes with vesicular nuclei, prominent nucleoli, and abundant cytoplasm. In some portions, the cells were arranged in sheets with a prominent starry-sky pattern and geographic coagulative necrosis. Interestingly, the well-known characteristics of perivascular infiltration of tumor cells were not identified, since the pineal parenchyma was almost completely replaced by neoplastic lymphocytes. An initial immunohistochemistry (IHC) panel was performed to exclude the diagnostic possibility of pineoblastoma and other germ cell tumors that frequently develop in the pineal gland. The tumor cells were all negative for synaptophysin, glial fibrillary acidic protein, pan-cytokeratin, and placental alkaline phosphatase. Instead, tumor cells showed strong positivity for B-cell markers including CD79a and CD20 but were negative for T-cell markers including CD3 and CD45RO. BCL2 was also positive, and the Ki-67 labeling proliferation index exceeded 50%. Pathology confirmed a diffuse large B cell lymphoma (DLBCL) involving the pineal gland. Additional IHC panel for DLBCL subdivision revealed BCL6 positivity, and CD10 and MUM1 nonreactivity (Figure <xref ref-type="fig" rid="F2">2</xref>A&#x2013;D). Consequently, the immunohistochemical subgroup of the lymphoma was a germinal center-like DLBCL.<sup><xref rid="R18" ref-type="bibr">18</xref></sup></p>
      <fig id="F2" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Microscopic characteristics of the pineal and gastric diffuse large B-cell lymphoma (DLBCL). (A) The pineal mass was composed of enlarged lymphocytes and scattered pale histiocytes featuring a starry-sky appearance (hematoxylin and eosin [H&amp;E] staining, original magnification &#xD7;&#x200A;200). (B) The tumor cells were diffusely positive for CD20 (immunohistochemistry, &#xD7;&#x200A;400). (C) Approximately 40% of the tumor cells showed positivity for BCL6 (immunohistochemistry, &#xD7;&#x200A;400). (D) The Ki-67 proliferation index of the tumor exceeded 50% (immunohistochemistry, &#xD7;&#x200A;400). (E) The lymphoma cells were densely infiltrated between the remaining gastric glands (H&amp;E stain, &#xD7;&#x200A;200). (F) The gastric lymphoma cells showed strong staining for CD79a (immunohistochemistry, &#xD7;&#x200A;400).</p>
        </caption>
        <graphic xlink:href="medi-95-e2923-g002"/>
      </fig>
      <p>Two weeks after the operation, the patient complained of gastric fullness and aggravated vomiting. Abdominal computed tomography revealed concentric wall thickening in the lower portion of the lesser curvature of the gastric body, but there was no evidence of enlarged lymph nodes or hepatosplenomegaly. Upper esophagogastroduodenoscopy showed a diffuse ulceroinfiltrative mass in the lesser curvature of the gastric body (Figure <xref ref-type="fig" rid="F3">3</xref>). Pathological diagnosis was DLBCL, identical to that of the previously removed pineal mass (Figure <xref ref-type="fig" rid="F2">2</xref>E and F). Other systemic evaluations, including chest and neck computed tomography scans and bone marrow biopsy, were normal. The PRL level gradually dropped to 459&#x200A;ng/mL 3 months after the brain operation. After removal of the pineal gland mass, the patient was treated with 2 cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by 1 cycle of high-dose methotrexate (3.5&#x200A;g/m<sup>2</sup>) chemotherapy. The patient was originally planned to be treated with 2 cycles of R-CHOP, followed by 4th infusion of high-dose MTX-based chemotherapy and additional 4 cycles of R-CHOP chemotherapy. However, further chemotherapy had to be discontinued after 1 cycle of high-dose MTX chemotherapy since the patient had neutropenia and general weakness. Two months after the brain operation, the patient underwent an emergent operation for mechanical ileus due to a newly developed mass. Subsequently, the patient had aspiration pneumonia and showed progression of the brain lesion aggravated by CSF seeding. The patient died 6 months after initial diagnosis.</p>
      <fig id="F3" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Esophagogastroduodenoscopy (EGD) showed a diffuse infiltrative mass with central ulceration (indicated by arrowheads) located in the lesser curvature of the gastric body.</p>
        </caption>
        <graphic xlink:href="medi-95-e2923-g003"/>
      </fig>
      <p>To evaluate the contribution of elevated PRL levels on the rapid progression of DLBCL, PRL expression in lymphoma cells was investigated by IHC. Both the pineal and gastric lesions were repeatedly negative for PRL staining (Figure <xref ref-type="fig" rid="F4">4</xref>A). For further evaluation of PRL receptor (PRL-R) expression, IHC and Western blot (WB) analysis were performed (dilution 1:200 for IHC, 1:2000 for WB; clone B6.2, catalogue no. MA5-11955, Thermo Fisher Scientific, Rockford, IL). WB was performed as described previously.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> To validate the results, WB analysis using a representative lymphoma cell line, EG7 (kindly provided by Dr Yang Deok-Hwan, Chonnam National University), and IHC staining for PRL-R were performed in an additional 10 DLBCL cases (Table <xref ref-type="table" rid="T1">1</xref>). As shown in Figure <xref ref-type="fig" rid="F4">4</xref>A, surgical samples from primary gastric and metastatic pineal lesions stained positive for PRL-R. PRL-R expression in lymphoma cells was also shown in the EG7 lymphoma cell line by WB (Figure <xref ref-type="fig" rid="F4">4</xref>B). In addition, 9 of 10 cases displayed diffuse or patchy strong PRL-R positivity (Figure <xref ref-type="fig" rid="F5">5</xref>), and the remaining case showed localized immunoreactivity around the vessels. The patients provided signed, informed consent, and the study was approved by the Institutional Review Board of the Chonnam National University Hwasun Hospital.</p>
      <table-wrap id="T1" position="float">
        <label>TABLE 1</label>
        <caption>
          <p>Brief Summary of Additional 10 Cases of DLBCL</p>
        </caption>
        <graphic xlink:href="medi-95-e2923-g004"/>
      </table-wrap>
      <fig id="F4" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Expression of prolactin receptor (PRL-R) in the current case. (A) Immunohistochemistry of PRL-R revealed a strong positivity in both primary gastric and metastatic pineal lymphomas (immunohistochemistry, &#xD7;&#x200A;200 and &#xD7;&#x200A;400, respectively). There was no expression of prolactin in the same samples (immunohistochemistry, &#xD7;&#x200A;200 and &#xD7;&#x200A;400, respectively). (B) Western blot analysis revealed PRL-R expression in the pineal lymphoma. This positive reaction was also noted in the lymphoma cell line EG7.</p>
        </caption>
        <graphic xlink:href="medi-95-e2923-g005"/>
      </fig>
      <fig id="F5" position="float">
        <label>FIGURE 5</label>
        <caption>
          <p>Immunohistochemistry of the prolactin receptor (PRL-R) in additional diffuse large B-cell lymphoma samples. Nine out of 10 selected cases showed positive immunoreactivity with variable portions of tumor components.</p>
        </caption>
        <graphic xlink:href="medi-95-e2923-g006"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Primary CNS lymphomas (PCNSL) are supratentorial in approximately 60% of patients.<sup><xref rid="R20" ref-type="bibr">20</xref></sup> Despite the more common location of PCNSL in the supratentorial region, involvement of the pineal gland is extremely rare. In a meta-analysis of PCNSL, only 0.5% of enrolled cases (2 of 424 cases) had tumors in the pineal location.<sup><xref rid="R21" ref-type="bibr">21</xref></sup> Secondary CNS involvement is infrequent in DLBCL, with an incidence range of 5% to 25% reported in studies assessing different risk factors and diagnostic tools.<sup><xref rid="R22" ref-type="bibr">22</xref>&#x2013;<xref rid="R24" ref-type="bibr">24</xref></sup></p>
      <p>The pineal region is one of the rarest locations for intracranial metastasis of systemic malignancies, with an incidence range of 1.8% to 4% of all intracranial metastases.<sup><xref rid="R25" ref-type="bibr">25</xref>&#x2013;<xref rid="R28" ref-type="bibr">28</xref></sup> Approximately half of the cases have no other metastases within the brain, as in this case.<sup><xref rid="R25" ref-type="bibr">25</xref></sup> Hematogenous spread through the posterior choroidal artery is suggested as the pathomechanism for pineal metastasis, given that the pineal gland is a circumventricular organ of the brain lacking a blood&#x2013;brain barrier.<sup><xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref></sup> Even though it is an isolated event, CNS involvement represents widespread disease progression and has the worst clinical outcome, with less than 10% of patients surviving 1 year.<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R31" ref-type="bibr">31</xref></sup> Of the 10 reported cases of pineal lymphoma, 6 involved multiple locations, and 2 were secondary, with 1 retroperitoneal primary and 1 gastric primary (Table <xref ref-type="table" rid="T2">2</xref>). The majority of the cases (6 out of 8 with determined histological types) were of a B-cell lineage, and the overall clinical progression seemed to be fatal, but follow-up information was insufficient.</p>
      <table-wrap id="T2" position="float">
        <label>TABLE 2</label>
        <caption>
          <p>Clinoco-Radiological Characteristics of Reported Cases of Pineal Lymphoma</p>
        </caption>
        <graphic xlink:href="medi-95-e2923-g007"/>
      </table-wrap>
      <p>In CNS lymphoma, concurrent brain tumor types including astrocytoma,<sup><xref rid="R32" ref-type="bibr">32</xref></sup> meningioma,<sup><xref rid="R33" ref-type="bibr">33</xref></sup> and pituitary adenoma<sup><xref rid="R34" ref-type="bibr">34</xref>&#x2013;<xref rid="R36" ref-type="bibr">36</xref></sup> have been reported. Interruption of the inhibitory pathway between the hypothalamus and pituitary gland was proposed as the putative pathogenesis for the development of pituitary adenoma in hypothalamic PCNSL.<sup><xref rid="R34" ref-type="bibr">34</xref></sup> In contrast, lymphoma development may be stimulated by microenvironmental alterations or hormones produced by the pituitary adenoma.<sup><xref rid="R35" ref-type="bibr">35</xref></sup> Another reported case of intermingled adenoma with lymphoma suggested a strong connection between pituitary adenoma and lymphoma in the same location.<sup><xref rid="R36" ref-type="bibr">36</xref></sup></p>
      <p>Whereas PRL-R is expressed in immune cells universally, the expression of human PRL is found mainly in T lymphocytes.<sup><xref rid="R37" ref-type="bibr">37</xref></sup> In addition, PRL production is evident in normal extrapituitary sites, including the decidua, myometrium, breast, prostate, brain, and malignant cells.<sup><xref rid="R38" ref-type="bibr">38</xref>,<xref rid="R39" ref-type="bibr">39</xref></sup> Although the precise function of PRL in immune cells is not clear, PRL has an important role in immunomodulation and lymphoid cell proliferation, in addition to the promotion of normal hematopoiesis.<sup><xref rid="R40" ref-type="bibr">40</xref>&#x2013;<xref rid="R42" ref-type="bibr">42</xref></sup> PRL promotes both cell-mediated and humoral immune responses through signaling pathways, including JAK/STAT and mitogen-activated protein kinase, resulting in target gene expression,<sup><xref rid="R43" ref-type="bibr">43</xref></sup> stimulation of B- and T-cell proliferation, proinflammatory cytokine production, and B-cell growth arrest.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> PRL can act as a survival (antiapoptotic) factor or as a mitogen, as exemplified in the lactating mammary gland, Nb2 lymphoma cells, and breast cancer cells.<sup><xref rid="R38" ref-type="bibr">38</xref></sup></p>
      <p>The presence of elevated serum PRL levels in the context of hematological malignancy is still controversial. A small number of previous studies reported elevated PRL levels in lymphoma patients,<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R44" ref-type="bibr">44</xref></sup> as well as in acute myeloid leukemia patients.<sup><xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R45" ref-type="bibr">45</xref></sup> Pathological hyperprolactinemia was shown to be associated with a reduction in natural killer cell number and function.<sup><xref rid="R46" ref-type="bibr">46</xref></sup> In addition to a direct mitogenic effect, PRL also has the capacity to inhibit cell death induced by cisplatin, doxorubicin, taxol, and other agents in cancer cells as exemplified by breast cancer research,<sup><xref rid="R47" ref-type="bibr">47</xref>,<xref rid="R48" ref-type="bibr">48</xref></sup> through drug detoxification arising from PRL-induced activation of glutathione S-transferase,<sup><xref rid="R48" ref-type="bibr">48</xref></sup> or potentially via PRL-mediated upregulation of antiapoptotic proteins such as BCL2.<sup><xref rid="R49" ref-type="bibr">49</xref></sup></p>
      <p>In this case, the endosellar mass was diagnosed as a prolactinoma based on an elevated PRL&#x200A;&gt;&#x200A;300&#x200A;ng/mL and relevant MR imaging,<sup><xref rid="R50" ref-type="bibr">50</xref>,<xref rid="R51" ref-type="bibr">51</xref></sup> even without pathological confirmation. There were a couple of reasons for that the pituitary tumor was prolactinoma. First, IHC staining using PRL antibody was repeatedly negative in the pineal and gastric lesions. It seemed unlikely that PRL was massively secreted from the pituitary lesion if the pituitary gland also had a lymphoma. Second, serum PRL levels exceeding 300&#x200A;ng/mL are almost always caused by a pure prolactinoma or a mixed pituitary adenoma with a lactotrophic component.<sup><xref rid="R50" ref-type="bibr">50</xref>,<xref rid="R51" ref-type="bibr">51</xref></sup> There are variable causes of hyperprolactinemia including drugs, pregnancy, nipple stimulation, and pituitary PRL secreting adenoma. Serum PRL levels in patients with prolactinoma can range from minimally elevated to 50,000&#x200A;ng/mL, but the PRL levels rarely exceed 200&#x200A;ng/mL in hyperprolactinemia due to other causes. Three months after complete removal of the pineal lymphoma, the PRL level gradually dropped to 459&#x200A;ng/mL without specific treatment for the prolactinoma. This finding corroborated a previous report that hyperprolactinemia is associated with lymphoma.<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R44" ref-type="bibr">44</xref></sup> The studies described above showed that certain subpopulations of lymphocytes synthesize and secrete biologically active PRL and that PRL can act as an autocrine and/or paracrine factor to modulate the activities of cells of the immune system. Despite repeated immunostaining in the current case, the tumor cells did not stain for PRL. In comparison, some lymphoma samples showed PRL-R expression. Presumably, shrinkage of the lymphoma volume may have affected the functional aspects of the prolactinoma. In addition, it is likely that the persistent hyperprolactinemia may have affected the chemoresistance of the DLBCL and have contributed to the fatal deterioration of the patient's condition.</p>
      <p>In conclusion, this is the 1st clinical report of concurrent prolactinoma and pineal lymphoma to our knowledge. This report raises questions about the mutual interaction between lymphoma progression and hyperprolactinemia. The occurrence of lymphoma in the clinical context of hyperprolactinemia may have important implications. Any clinical condition that results in elevated PRL levels needs to be controlled. In small clinical studies on breast cancer, patients treated with antiprolactinemic agents in combination with docetaxel responded better than those treated with docetaxel alone.<sup><xref rid="R52" ref-type="bibr">52</xref>,<xref rid="R53" ref-type="bibr">53</xref></sup> Additional research and clinical data are required to clarify the exact correlation between DLBCL progression and hyperprolactinemia.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="abbr">
        <p>Abbreviations: CNS = central nervous system, DLBCL = diffuse large B-cell lymphoma, IHC = immunohistochemistry, MR = magnetic resonance, PRL = prolactin, PRL-R = prolactin receptor.</p>
      </fn>
      <fn fn-type="supported-by">
        <p>This work was supported by the National R&amp;D Program for Cancer Control, Ministry of Health &amp; Welfare (0720570).</p>
      </fn>
      <fn fn-type="conflict">
        <p>The authors have no conflicts of interest to disclose.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="R1">
        <label>1.</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gerstner</surname><given-names>ER</given-names></name><name><surname>Batchelor</surname><given-names>TT</given-names></name></person-group>
<person-group person-group-type="editor"><name><surname>Winn</surname><given-names>HR</given-names></name></person-group>
<article-title>Central nervous system lymphoma</article-title>. <source><italic>Youmans Neurological Surgery</italic></source>. <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Saunders</publisher-name>; <year>2011</year>
<fpage>1400</fpage>&#x2013;<lpage>1409</lpage>.</mixed-citation>
      </ref>
      <ref id="R2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loeffler</surname><given-names>JS</given-names></name><name><surname>Ervin</surname><given-names>TJ</given-names></name><name><surname>Mauch</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Primary lymphomas of the central nervous system: patterns of failure and factors that influence survival</article-title>. <source><italic>J Clin Oncol</italic></source>
<year>1985</year>; <volume>3</volume>:<fpage>490</fpage>&#x2013;<lpage>494</lpage>.<pub-id pub-id-type="pmid">3981223</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>RH</given-names></name><name><surname>Woo</surname><given-names>EK</given-names></name><name><surname>Yu</surname><given-names>YL</given-names></name><etal/></person-group>
<article-title>Central nervous system involvement in non-Hodgkin's lymphoma</article-title>. <source><italic>Eur J Cancer Clin Oncol</italic></source>
<year>1989</year>; <volume>25</volume>:<fpage>703</fpage>&#x2013;<lpage>710</lpage>.<pub-id pub-id-type="pmid">2714346</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollender</surname><given-names>A</given-names></name><name><surname>Kvaloy</surname><given-names>S</given-names></name><name><surname>Lote</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis</article-title>. <source><italic>Eur J Cancer</italic></source>
<year>2000</year>; <volume>36</volume>:<fpage>1762</fpage>&#x2013;<lpage>1768</lpage>.<pub-id pub-id-type="pmid">10974623</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pantanowitz</surname><given-names>L</given-names></name><name><surname>Freedman</surname><given-names>SJ</given-names></name><name><surname>Dezube</surname><given-names>BJ</given-names></name><etal/></person-group>
<article-title>November 2002: a 72-year-old woman with a pineal gland mass</article-title>. <source><italic>Brain Pathol</italic></source>
<year>2003</year>; <volume>13</volume>:<fpage>235</fpage>&#x2013;<lpage>236</lpage>.<comment>239</comment>.<pub-id pub-id-type="pmid">12744478</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimoldi</surname><given-names>N</given-names></name><name><surname>Tomei</surname><given-names>G</given-names></name><name><surname>Stankov</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Neuroendocrine, immunohistochemical, and ultrastructural study of pineal region tumors</article-title>. <source><italic>J Pineal Res</italic></source>
<year>1998</year>; <volume>25</volume>:<fpage>147</fpage>&#x2013;<lpage>158</lpage>.<pub-id pub-id-type="pmid">9745983</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amagasa</surname><given-names>M</given-names></name><name><surname>Kawase</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Spinal malignant lymphoma appearing after radiation and chemotherapy of a pineal region tumor</article-title>. <source><italic>Surg Neurol</italic></source>
<year>1996</year>; <volume>45</volume>:<fpage>167</fpage>&#x2013;<lpage>169</lpage>.<comment>discussion 169&#x2013;171</comment>.<pub-id pub-id-type="pmid">8607068</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuno</surname><given-names>A</given-names></name><name><surname>Hashizume</surname><given-names>K</given-names></name><name><surname>Tsuzuki</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>[A case of primary intracranial T cell type malignant lymphoma, radiologically resembling germ cell tumor and presenting hypopituitarism]</article-title>. <source><italic>No Shinkei Geka</italic></source>
<year>1993</year>; <volume>21</volume>:<fpage>551</fpage>&#x2013;<lpage>555</lpage>.<pub-id pub-id-type="pmid">8393152</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popovic</surname><given-names>EA</given-names></name><name><surname>Kelly</surname><given-names>PJ</given-names></name></person-group>
<article-title>Stereotactic procedures for lesions of the pineal region</article-title>. <source><italic>Mayo Clin Proc</italic></source>
<year>1993</year>; <volume>68</volume>:<fpage>965</fpage>&#x2013;<lpage>970</lpage>.<pub-id pub-id-type="pmid">8412362</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endo</surname><given-names>H</given-names></name><name><surname>Fujimura</surname><given-names>M</given-names></name><name><surname>Kumabe</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Application of high-definition flexible neuroendoscopic system to the treatment of primary pineal malignant B-cell lymphoma</article-title>. <source><italic>Surg Neurol</italic></source>
<year>2009</year>; <volume>71</volume>:<fpage>344</fpage>&#x2013;<lpage>348</lpage>.<pub-id pub-id-type="pmid">18207502</pub-id></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karikari</surname><given-names>IO</given-names></name><name><surname>Thomas</surname><given-names>KK</given-names></name><name><surname>Lagoo</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Primary cerebral ALK-1-positive anaplastic large cell lymphoma in a child. Case report and literature review</article-title>. <source><italic>Pediatric Neurosurg</italic></source>
<year>2007</year>; <volume>43</volume>:<fpage>516</fpage>&#x2013;<lpage>521</lpage>.</mixed-citation>
      </ref>
      <ref id="R12">
        <label>12.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Tezuka</surname><given-names>Y</given-names></name><name><surname>Hirosawa</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Pineal malignant B-cell lymphoma with lower cranial nerve involvement</article-title>. <source><italic>Intern Med (Tokyo, Japan)</italic></source>
<year>2014</year>; <volume>53</volume>:<fpage>1205</fpage>&#x2013;<lpage>1208</lpage>.</mixed-citation>
      </ref>
      <ref id="R13">
        <label>13.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasudevan</surname><given-names>JA</given-names></name><name><surname>Nair</surname><given-names>RA</given-names></name><name><surname>Nair</surname><given-names>SG</given-names></name><etal/></person-group>
<article-title>Primary diffuse large B-cell lymphoma of the central nervous system in pineal gland: report of a rare case with review of literature</article-title>. <source><italic>Indian J Pathol Microbiol</italic></source>
<year>2015</year>; <volume>58</volume>:<fpage>412</fpage>&#x2013;<lpage>413</lpage>.<pub-id pub-id-type="pmid">26275286</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>14.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMurray</surname><given-names>RW</given-names></name></person-group>
<article-title>Estrogen, prolactin, and autoimmunity: actions and interactions</article-title>. <source><italic>Int Immunopharmacol</italic></source>
<year>2001</year>; <volume>1</volume>:<fpage>995</fpage>&#x2013;<lpage>1008</lpage>.<pub-id pub-id-type="pmid">11407318</pub-id></mixed-citation>
      </ref>
      <ref id="R15">
        <label>15.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gado</surname><given-names>K</given-names></name><name><surname>Pallinger</surname><given-names>E</given-names></name><name><surname>Kovacs</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Prolactin influences proliferation and apoptosis of a human IgE secreting myeloma cell line, U266</article-title>. <source><italic>Immunol Lett</italic></source>
<year>2002</year>; <volume>82</volume>:<fpage>191</fpage>&#x2013;<lpage>196</lpage>.<pub-id pub-id-type="pmid">12036601</pub-id></mixed-citation>
      </ref>
      <ref id="R16">
        <label>16.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grobe</surname><given-names>N</given-names></name><name><surname>Ruhle</surname><given-names>H</given-names></name><name><surname>Eckelmann</surname><given-names>G</given-names></name></person-group>
<article-title>[Hyperprolactinemia in malignant lymphomas]</article-title>. <source><italic>Dtsch Med Wochenschr</italic></source>
<year>1990</year>; <volume>115</volume>:<fpage>1825</fpage>&#x2013;<lpage>1827</lpage>.<pub-id pub-id-type="pmid">2245764</pub-id></mixed-citation>
      </ref>
      <ref id="R17">
        <label>17.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatfill</surname><given-names>SJ</given-names></name><name><surname>Kirby</surname><given-names>R</given-names></name><name><surname>Hanley</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Hyperprolactinemia in acute myeloid leukemia and indication of ectopic expression of human prolactin in blast cells of a patient of subtype M4</article-title>. <source><italic>Leuk Res</italic></source>
<year>1990</year>; <volume>14</volume>:<fpage>57</fpage>&#x2013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">1968111</pub-id></mixed-citation>
      </ref>
      <ref id="R18">
        <label>18.</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>H</given-names></name><name><surname>Warnke</surname><given-names>RA</given-names></name><name><surname>Chan</surname><given-names>WC</given-names></name></person-group>
<person-group person-group-type="editor"><name><surname>Swerdllow</surname><given-names>SH</given-names></name><name><surname>Campo</surname><given-names>E</given-names></name><name><surname>Harris</surname><given-names>NL</given-names></name><etal/></person-group>
<article-title>Diffuse large B-cell lymphoma, not otherwise specified.</article-title>
<source><italic>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues</italic></source>
<edition>4th ed</edition><publisher-loc>Lyon</publisher-loc>: <publisher-name>IARC Press</publisher-name>; <year>2008</year>
<fpage>233</fpage>&#x2013;<lpage>237</lpage>.</mixed-citation>
      </ref>
      <ref id="R19">
        <label>19.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Ahn</surname><given-names>EJ</given-names></name><name><surname>Oh</surname><given-names>SJ</given-names></name><etal/></person-group>
<article-title>KITENIN promotes glioma invasiveness and progression, associated with the induction of EMT and stemness markers</article-title>. <source><italic>Oncotarget</italic></source>
<year>2015</year>; <volume>6</volume>:<fpage>3240</fpage>&#x2013;<lpage>3253</lpage>.<pub-id pub-id-type="pmid">25605251</pub-id></mixed-citation>
      </ref>
      <ref id="R20">
        <label>20.</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Deckert</surname><given-names>M</given-names></name><name><surname>Paulus</surname><given-names>W</given-names></name></person-group>
<person-group person-group-type="editor"><name><surname>Louis</surname><given-names>DN</given-names></name><name><surname>Ohgaki</surname><given-names>H</given-names></name><name><surname>Wiestler</surname><given-names>OD</given-names></name><name><surname>Cavenee</surname><given-names>WK</given-names></name></person-group>
<article-title>Malignant lymphomas</article-title>. <source><italic>WHO Classification of Tumours of the Central Nervous System</italic></source>
<edition>4th ed</edition><publisher-loc>Lyon, France</publisher-loc>: <publisher-name>International Agency for Research on Cancer</publisher-name>; <year>2007</year>
<fpage>188</fpage>&#x2013;<lpage>192</lpage>.</mixed-citation>
      </ref>
      <ref id="R21">
        <label>21.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>K</given-names></name><name><surname>Kun</surname><given-names>L</given-names></name><name><surname>Cox</surname><given-names>J</given-names></name></person-group>
<article-title>Primary malignant lymphoma of the central nervous system. Results of treatment of 11 cases and review of the literature</article-title>. <source><italic>J Neurosurg</italic></source>
<year>1986</year>; <volume>65</volume>:<fpage>600</fpage>&#x2013;<lpage>607</lpage>.<pub-id pub-id-type="pmid">3772445</pub-id></mixed-citation>
      </ref>
      <ref id="R22">
        <label>22.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bierman</surname><given-names>P</given-names></name><name><surname>Giglio</surname><given-names>P</given-names></name></person-group>
<article-title>Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma</article-title>. <source><italic>Hematol Oncol Clin North Am</italic></source>
<year>2005</year>; <volume>19</volume>:<fpage>597</fpage>&#x2013;<lpage>609</lpage>.<comment>v</comment>.<pub-id pub-id-type="pmid">16083825</pub-id></mixed-citation>
      </ref>
      <ref id="R23">
        <label>23.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hegde</surname><given-names>U</given-names></name><name><surname>Filie</surname><given-names>A</given-names></name><name><surname>Little</surname><given-names>RF</given-names></name><etal/></person-group>
<article-title>High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology</article-title>. <source><italic>Blood</italic></source>
<year>2005</year>; <volume>105</volume>:<fpage>496</fpage>&#x2013;<lpage>502</lpage>.<pub-id pub-id-type="pmid">15358629</pub-id></mixed-citation>
      </ref>
      <ref id="R24">
        <label>24.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villa</surname><given-names>D</given-names></name><name><surname>Connors</surname><given-names>JM</given-names></name><name><surname>Shenkier</surname><given-names>TN</given-names></name><etal/></person-group>
<article-title>Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy</article-title>. <source><italic>Ann Oncol</italic></source>
<year>2010</year>; <volume>21</volume>:<fpage>1046</fpage>&#x2013;<lpage>1052</lpage>.<pub-id pub-id-type="pmid">19861575</pub-id></mixed-citation>
      </ref>
      <ref id="R25">
        <label>25.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirato</surname><given-names>J</given-names></name><name><surname>Nakazato</surname><given-names>Y</given-names></name></person-group>
<article-title>Pathology of pineal region tumors</article-title>. <source><italic>J Neurooncol</italic></source>
<year>2001</year>; <volume>54</volume>:<fpage>239</fpage>&#x2013;<lpage>249</lpage>.<pub-id pub-id-type="pmid">11767290</pub-id></mixed-citation>
      </ref>
      <ref id="R26">
        <label>26.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chason</surname><given-names>JL</given-names></name><name><surname>Walker</surname><given-names>FB</given-names></name><name><surname>Landers</surname><given-names>JW</given-names></name></person-group>
<article-title>Metastatic carcinoma in the central nervous system and dorsal root ganglia. A prospective autopsy study</article-title>. <source><italic>Cancer</italic></source>
<year>1963</year>; <volume>16</volume>:<fpage>781</fpage>&#x2013;<lpage>787</lpage>.<pub-id pub-id-type="pmid">14020314</pub-id></mixed-citation>
      </ref>
      <ref id="R27">
        <label>27.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>France</surname><given-names>LH</given-names></name></person-group>
<article-title>Contribution to the study of 150 cases of cerebral metastases. II. Neuropathological study</article-title>. <source><italic>J Neurosurg Sci</italic></source>
<year>1975</year>; <volume>19</volume>:<fpage>189</fpage>&#x2013;<lpage>210</lpage>.<pub-id pub-id-type="pmid">1232094</pub-id></mixed-citation>
      </ref>
      <ref id="R28">
        <label>28.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortega</surname><given-names>P</given-names></name><name><surname>Malamud</surname><given-names>N</given-names></name><name><surname>Shimkin</surname><given-names>MB</given-names></name></person-group>
<article-title>Metastasis to the pineal body</article-title>. <source><italic>AMA Arch Pathol</italic></source>
<year>1951</year>; <volume>52</volume>:<fpage>518</fpage>&#x2013;<lpage>528</lpage>.<pub-id pub-id-type="pmid">14877387</pub-id></mixed-citation>
      </ref>
      <ref id="R29">
        <label>29.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freedman</surname><given-names>SJ</given-names></name><name><surname>Pantanowitz</surname><given-names>L</given-names></name><name><surname>Joseph</surname><given-names>JT</given-names></name><etal/></person-group>
<article-title>Unusual locations for lymphomas. Case 2. Pineal lymphoma</article-title>. <source><italic>J Clin Oncol</italic></source>
<year>2001</year>; <volume>19</volume>:<fpage>2960</fpage>&#x2013;<lpage>2963</lpage>.<pub-id pub-id-type="pmid">11387370</pub-id></mixed-citation>
      </ref>
      <ref id="R30">
        <label>30.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Besien</surname><given-names>K</given-names></name><name><surname>Gisselbrecht</surname><given-names>C</given-names></name><name><surname>Pfreundschuh</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment</article-title>. <source><italic>Leuk Lymphoma</italic></source>
<year>2008</year>; <volume>49</volume>
<issue>(Suppl 1)</issue>:<fpage>52</fpage>&#x2013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">18821433</pub-id></mixed-citation>
      </ref>
      <ref id="R31">
        <label>31.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aviles</surname><given-names>A</given-names></name><name><surname>Jesus Nambo</surname><given-names>M</given-names></name><name><surname>Neri</surname><given-names>N</given-names></name></person-group>
<article-title>Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: an analysis of 3,258 patients in a single center</article-title>. <source><italic>Med Oncol</italic></source>
<year>2013</year>; <volume>30</volume>:<fpage>520</fpage>.<pub-id pub-id-type="pmid">23456620</pub-id></mixed-citation>
      </ref>
      <ref id="R32">
        <label>32.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giromini</surname><given-names>D</given-names></name><name><surname>Peiffer</surname><given-names>J</given-names></name><name><surname>Tzonos</surname><given-names>T</given-names></name></person-group>
<article-title>Occurrence of a primary Burkitt-type lymphoma of the central nervous system in an astrocytoma patient. A case report</article-title>. <source><italic>Acta Neuropathol</italic></source>
<year>1981</year>; <volume>54</volume>:<fpage>165</fpage>&#x2013;<lpage>167</lpage>.<pub-id pub-id-type="pmid">7246058</pub-id></mixed-citation>
      </ref>
      <ref id="R33">
        <label>33.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slowik</surname><given-names>F</given-names></name><name><surname>Jellinger</surname><given-names>K</given-names></name></person-group>
<article-title>Association of primary cerebral lymphoma with meningioma: report of two cases</article-title>. <source><italic>Clin Neuropathol</italic></source>
<year>1990</year>; <volume>9</volume>:<fpage>69</fpage>&#x2013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">2187641</pub-id></mixed-citation>
      </ref>
      <ref id="R34">
        <label>34.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roggli</surname><given-names>VL</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Armstrong</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Pituitary microadenoma and primary lymphoma of brain associated with hypothalamic invasion</article-title>. <source><italic>Am J Clin Pathol</italic></source>
<year>1979</year>; <volume>71</volume>:<fpage>724</fpage>&#x2013;<lpage>727</lpage>.<pub-id pub-id-type="pmid">377944</pub-id></mixed-citation>
      </ref>
      <ref id="R35">
        <label>35.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>D</given-names></name><name><surname>Buchfelder</surname><given-names>M</given-names></name><name><surname>Brabletz</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Intrasellar malignant lymphoma developing within pituitary adenoma</article-title>. <source><italic>Acta Neuropathol</italic></source>
<year>1999</year>; <volume>97</volume>:<fpage>311</fpage>&#x2013;<lpage>316</lpage>.<pub-id pub-id-type="pmid">10090680</pub-id></mixed-citation>
      </ref>
      <ref id="R36">
        <label>36.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Au</surname><given-names>WY</given-names></name><name><surname>Kwong</surname><given-names>YL</given-names></name><name><surname>Shek</surname><given-names>TW</given-names></name><etal/></person-group>
<article-title>Diffuse large-cell B-cell lymphoma in a pituitary adenoma: an unusual cause of pituitary apoplexy</article-title>. <source><italic>Am J Hematol</italic></source>
<year>2000</year>; <volume>63</volume>:<fpage>231</fpage>&#x2013;<lpage>232</lpage>.<pub-id pub-id-type="pmid">10706771</pub-id></mixed-citation>
      </ref>
      <ref id="R37">
        <label>37.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellegrini</surname><given-names>I</given-names></name><name><surname>Lebrun</surname><given-names>JJ</given-names></name><name><surname>Ali</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Expression of prolactin and its receptor in human lymphoid cells</article-title>. <source><italic>Mol Endocrinol (Baltimore, MD)</italic></source>
<year>1992</year>; <volume>6</volume>:<fpage>1023</fpage>&#x2013;<lpage>1031</lpage>.</mixed-citation>
      </ref>
      <ref id="R38">
        <label>38.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Jonathan</surname><given-names>N</given-names></name><name><surname>Liby</surname><given-names>K</given-names></name><name><surname>McFarland</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Prolactin as an autocrine/paracrine growth factor in human cancer</article-title>. <source><italic>Trends Endocrinol Metab</italic></source>
<year>2002</year>; <volume>13</volume>:<fpage>245</fpage>&#x2013;<lpage>250</lpage>.<pub-id pub-id-type="pmid">12128285</pub-id></mixed-citation>
      </ref>
      <ref id="R39">
        <label>39.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Jonathan</surname><given-names>N</given-names></name><name><surname>Mershon</surname><given-names>JL</given-names></name><name><surname>Allen</surname><given-names>DL</given-names></name><etal/></person-group>
<article-title>Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects</article-title>. <source><italic>Endocr Rev</italic></source>
<year>1996</year>; <volume>17</volume>:<fpage>639</fpage>&#x2013;<lpage>669</lpage>.<pub-id pub-id-type="pmid">8969972</pub-id></mixed-citation>
      </ref>
      <ref id="R40">
        <label>40.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu-Lee</surname><given-names>LY</given-names></name></person-group>
<article-title>Molecular actions of prolactin in the immune system</article-title>. <source><italic>Proc Soc Exp Biol Med</italic></source>
<year>1997</year>; <volume>215</volume>:<fpage>35</fpage>&#x2013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">9142136</pub-id></mixed-citation>
      </ref>
      <ref id="R41">
        <label>41.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berczi</surname><given-names>I</given-names></name><name><surname>Nagy</surname><given-names>E</given-names></name><name><surname>de Toledo</surname><given-names>SM</given-names></name><etal/></person-group>
<article-title>Pituitary hormones regulate c-myc and DNA synthesis in lymphoid tissue</article-title>. <source><italic>J Immunol (Baltimore, MD: 1950)</italic></source>
<year>1991</year>; <volume>146</volume>:<fpage>2201</fpage>&#x2013;<lpage>2206</lpage>.</mixed-citation>
      </ref>
      <ref id="R42">
        <label>42.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velkeniers</surname><given-names>B</given-names></name><name><surname>Dogusan</surname><given-names>Z</given-names></name><name><surname>Naessens</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Prolactin, growth hormone and the immune system in humans</article-title>. <source><italic>Cell Mol Life Sci</italic></source>
<year>1998</year>; <volume>54</volume>:<fpage>1102</fpage>&#x2013;<lpage>1108</lpage>.<pub-id pub-id-type="pmid">9817989</pub-id></mixed-citation>
      </ref>
      <ref id="R43">
        <label>43.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu-Lee</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>G</given-names></name><name><surname>Moutoussamy</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Prolactin and growth hormone signal transduction in lymphohaemopoietic cells</article-title>. <source><italic>Cell Mol Life Sci</italic></source>
<year>1998</year>; <volume>54</volume>:<fpage>1067</fpage>&#x2013;<lpage>1075</lpage>.<pub-id pub-id-type="pmid">9817985</pub-id></mixed-citation>
      </ref>
      <ref id="R44">
        <label>44.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>RW</given-names></name><name><surname>Grebe</surname><given-names>SK</given-names></name><name><surname>Dady</surname><given-names>PJ</given-names></name></person-group>
<article-title>[Hyperprolactinemia in malignant lymphomas]</article-title>. <source><italic>Dtsch Med Wochenschr</italic></source>
<year>1992</year>; <volume>117</volume>:<fpage>198</fpage>.<pub-id pub-id-type="pmid">1735383</pub-id></mixed-citation>
      </ref>
      <ref id="R45">
        <label>45.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kooijman</surname><given-names>R</given-names></name><name><surname>Gerlo</surname><given-names>S</given-names></name><name><surname>Coppens</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Myeloid leukemic cells express and secrete bioactive pituitary-sized 23 kDa prolactin</article-title>. <source><italic>J Neuroimmunol</italic></source>
<year>2000</year>; <volume>110</volume>:<fpage>252</fpage>&#x2013;<lpage>258</lpage>.<pub-id pub-id-type="pmid">11024557</pub-id></mixed-citation>
      </ref>
      <ref id="R46">
        <label>46.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerli</surname><given-names>R</given-names></name><name><surname>Rambotti</surname><given-names>P</given-names></name><name><surname>Nicoletti</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Reduced number of natural killer cells in patients with pathological hyperprolactinemia</article-title>. <source><italic>Clin Exp Immunol</italic></source>
<year>1986</year>; <volume>64</volume>:<fpage>399</fpage>&#x2013;<lpage>406</lpage>.<pub-id pub-id-type="pmid">3091304</pub-id></mixed-citation>
      </ref>
      <ref id="R47">
        <label>47.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howell</surname><given-names>SJ</given-names></name><name><surname>Anderson</surname><given-names>E</given-names></name><name><surname>Hunter</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity</article-title>. <source><italic>Breast Cancer Res</italic></source>
<year>2008</year>; <volume>10</volume>:<fpage>R68</fpage>.<pub-id pub-id-type="pmid">18681966</pub-id></mixed-citation>
      </ref>
      <ref id="R48">
        <label>48.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LaPensee</surname><given-names>EW</given-names></name><name><surname>Schwemberger</surname><given-names>SJ</given-names></name><name><surname>LaPensee</surname><given-names>CR</given-names></name><etal/></person-group>
<article-title>Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase</article-title>. <source><italic>Carcinogenesis</italic></source>
<year>2009</year>; <volume>30</volume>:<fpage>1298</fpage>&#x2013;<lpage>1304</lpage>.<pub-id pub-id-type="pmid">19443905</pub-id></mixed-citation>
      </ref>
      <ref id="R49">
        <label>49.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peirce</surname><given-names>SK</given-names></name><name><surname>Chen</surname><given-names>WY</given-names></name></person-group>
<article-title>Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice</article-title>. <source><italic>Oncogene</italic></source>
<year>2004</year>; <volume>23</volume>:<fpage>1248</fpage>&#x2013;<lpage>1255</lpage>.<pub-id pub-id-type="pmid">14647416</pub-id></mixed-citation>
      </ref>
      <ref id="R50">
        <label>50.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vance</surname><given-names>ML</given-names></name><name><surname>Thorner</surname><given-names>MO</given-names></name></person-group>
<article-title>Prolactinomas</article-title>. <source><italic>Endocrinol Metab Clin North Am</italic></source>
<year>1987</year>; <volume>16</volume>:<fpage>731</fpage>&#x2013;<lpage>753</lpage>.<pub-id pub-id-type="pmid">3319600</pub-id></mixed-citation>
      </ref>
      <ref id="R51">
        <label>51.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>MH</given-names></name><name><surname>Teal</surname><given-names>J</given-names></name><name><surname>Gott</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Natural history of microprolactinomas: six-year follow-up</article-title>. <source><italic>Neurosurgery</italic></source>
<year>1983</year>; <volume>12</volume>:<fpage>180</fpage>&#x2013;<lpage>183</lpage>.<pub-id pub-id-type="pmid">6682188</pub-id></mixed-citation>
      </ref>
      <ref id="R52">
        <label>52.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lissoni</surname><given-names>P</given-names></name><name><surname>Bucovec</surname><given-names>R</given-names></name><name><surname>Malugani</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines</article-title>. <source><italic>Anticancer Res</italic></source>
<year>2002</year>; <volume>22</volume>
<issue>(2b)</issue>:<fpage>1131</fpage>&#x2013;<lpage>1134</lpage>.<pub-id pub-id-type="pmid">12168912</pub-id></mixed-citation>
      </ref>
      <ref id="R53">
        <label>53.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frontini</surname><given-names>L</given-names></name><name><surname>Lissoni</surname><given-names>P</given-names></name><name><surname>Vaghi</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer</article-title>. <source><italic>Anticancer Res</italic></source>
<year>2004</year>; <volume>24</volume>:<fpage>4223</fpage>&#x2013;<lpage>4226</lpage>.<pub-id pub-id-type="pmid">15736476</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
